Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Multicancer Early Detection Deoxyribonucleic Acid (DNA) Blood Tests Market Forecast: What Market Value Is Expected By 2030?
The multicancer early detection deoxyribonucleic acid (DNA) blood tests market has experienced rapid expansion in recent years. This market is expected to grow from $0.79 billion in 2025 to $0.9 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 13.2%. The historical increase can be attributed to several factors: increasing global cancer incidence and mortality rates, the limited effectiveness of late-stage cancer diagnosis methods, the growing adoption of genomic sequencing technologies in oncology research, the expansion of centralized cancer diagnostic laboratories, and rising awareness of early cancer screening benefits among healthcare providers.
The market for multicancer early detection deoxyribonucleic acid (DNA) blood tests is projected to experience swift expansion in the coming years. This market is anticipated to reach $1.49 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.4%. Several factors are expected to fuel this growth during the forecast period, including advancements in multi-cancer early detection liquid biopsy technologies, increasing integration of AI-based genomic interpretation platforms, growing adoption of personalized and precision oncology screening programs, expansion of preventive healthcare initiatives and population screening mandates, and rising investment in biomarker discovery and cancer genomics research. Key trends foreseen over this period involve the increasing embrace of liquid biopsy-based multi-cancer screening for early detection, expanded application of circulating tumor DNA sequencing in non-invasive cancer diagnostics, deeper integration of AI-driven biomarker interpretation for cancer risk prediction, broader implementation of population-wide preventive oncology screening programs, and a surging preference for minimally invasive blood-based cancer testing instead of traditional biopsy methods.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample_request?id=77618218&type=smp
Multicancer Early Detection Deoxyribonucleic Acid (DNA) Blood Tests Market Development Factors: Which Trends Are Supporting Demand?
A growing global incidence of cancer is projected to fuel the expansion of the multicancer early detection DNA blood tests market. Cancer, a condition defined by the unchecked proliferation and dissemination of aberrant cells capable of invading surrounding tissues and metastasizing, is becoming more widespread as global health systems document greater incidence rates and improved screening and detection methods identify more cases earlier. These multicancer early detection DNA blood tests aid in addressing this rising prevalence by offering non-invasive, blood-based screening solutions for the early detection of various cancer types via circulating tumor DNA analysis, thereby enhancing early diagnosis and patient outcomes. For instance, in April 2024, the International Agency for Research on Cancer, a France-based intergovernmental organization under the World Health Organization, reported nearly 20 million new cancer cases and almost 10 million cancer-related deaths in 2022. Demographic forecasts suggest that the yearly number of new cancer cases will climb to 35 million by 2050, signifying a 77% increase from 2022. Consequently, the global increase in cancer prevalence is a key driver for the growth of the multicancer early detection DNA blood tests market.
#Multicancer Early Detection Deoxyribonucleic Acid (DNA) Blood Tests Market Segment Landscape And Growth Potential
The multicancer early detection deoxyribonucleic acid (dna) blood tests market covered in this report is segmented –
1) By Test Type: Pan-Cancer Minimal Residual Disease Early Detection Tests, Targeted Multi-Cancer Panels, Single-Cancer Deoxyribonucleic Acid Blood Tests
2) By Technology: Circulating Cell-Free Deoxyribonucleic Acid Methylation Profiling, Circulating Cell-Free Deoxyribonucleic Acid Mutation Analysis, Fragmentomics, Multi-Analyte Approaches, Other Epigenomic Approaches
3) By Sample Type: Blood, Plasma, Urine
4) By Application: Asymptomatic Population Screening, Diagnostic Support, Cancer Recurrence Monitoring
5) By End Users: Reference Laboratories, Hospital Laboratories, Clinics, Direct-To-Consumer Users
Subsegments:
1) By Pan-Cancer Minimal Residual Disease Early Detection Tests: Solid Tumor Detection Panels, Hematological Cancer Detection Panels, Early Stage Cancer Screening Panels, Late Stage Cancer Detection Panels, Whole Body Cancer Screening Tests
2) By Targeted Multi-Cancer Panels: Organ Specific Cancer Panels, High Risk Population Screening Panels, Genetic Marker Based Panels, Epigenetic Marker Based Panels, Combination Biomarker Panels
3) By Single-Cancer Deoxyribonucleic Acid Blood Tests: Breast Cancer Detection Tests, Lung Cancer Detection Tests, Colorectal Cancer Detection Tests, Prostate Cancer Detection Tests, Liver Cancer Detection Tests
Multicancer Early Detection Deoxyribonucleic Acid (DNA) Blood Tests Market Transformation Trends: Which Innovations Are Driving Change?
Leading companies within the multicancer early detection DNA blood tests market are prioritizing the development of innovative solutions, including breakthroughs in cell-free DNA (cfDNA) and methylation-based sequencing technologies, to fulfill the growing demand for early, non-invasive, and multi-cancer screening options. Cell-free DNA-based testing involves the examination of fragmented DNA released into the bloodstream by tumor cells, enabling the identification of multiple cancers from a single blood draw, a contrast to traditional diagnostic approaches that rely on invasive biopsies or organ-specific imaging techniques. As an example, in March 2025, Gene Solutions, a biotechnology firm from Vietnam, introduced an advanced multi-cancer early detection blood test designed for population-scale screening. This test employs cfDNA analysis alongside machine learning algorithms to pinpoint cancer-specific genomic and epigenomic signatures across various cancer types. It facilitates early-stage cancer detection with strong predictive accuracy while reducing false positives, making it suitable for regular health screening. Moreover, the test incorporates tumor origin prediction technology to aid in identifying the probable source of cancer for subsequent diagnosis and is intended to improve accessibility to early cancer detection, particularly in regions with limited screening infrastructure.
Multicancer Early Detection Deoxyribonucleic Acid (DNA) Blood Tests Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the multicancer early detection deoxyribonucleic acid (dna) blood tests market are Thermo Fisher Scientific Inc., Prenetics Global Limited, Eurofins Scientific Inc., SeekIn Inc., VolitionRx Limited, Myriad Genetics Inc., Guardant Health, Freenome Holdings Inc., GENECAST Biotechnology Co. Ltd., Burning Rock Biotech Limited, Geneseeq Technology Inc. , Quibim S. L., 1drop Inc., Bioneer Corporation, CellMax Life, Datar Cancer Genetics, Laboratory for Advanced Medicine Inc., Harbinger Health Inc., Norgen Biotek Corp., Singlera Genomics Inc., Elypta AB, StageZero Life Sciences, INOVIQ, AnPac Bio-Medical Science, EarlyDiagnostics, Micronoma
Access The Complete Multicancer Early Detection Deoxyribonucleic Acid (DNA) Blood Tests Market Report:
Multicancer Early Detection Deoxyribonucleic Acid (DNA) Blood Tests Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the multicancer early detection DNA blood tests market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multicancer early detection deoxyribonucleic acid (DNA) blood tests market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.